In his weekly clinical update, Dr. Griffin discusses disease severity of RSV compared with COVID-19 and Influenza among hospitalized adults aged ≥60 years, antiviral efficacy of Molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19, Nirmatrelvir-Ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to covid-19 complications, antibiotic use among hospitalized patients with COVID-19 in the United States, one week of oral Camostat vs Placebo in nonhospitalized adults with mild-to-moderate COVID-19, assessment of the available therapeutic approaches for severe COVID-19, optimal duration of systemic Corticosteroids in COVID-19 treatment, effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome, local budesonide therapy in the management of persistent hyposmia in suspected non-severe COVID-19 patients, and the safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with advanced chronic Kidney disease and COVID-19.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Disease severity of RSV compared with COVID-19 and Influenza among hospitalized adults
• Antiviral efficacy of molnupiravir vs ritonavir-nirmatrelvir in patients with symptomatic COVID-19 (The Lancet)
• Nirmatrelvir-Ritonavir and COVID-19 mortality and hospitalization among patients with vulnerability to complications (JAMA)
• Antibiotic use among hospitalized patients with COVID-19 (OFID)
• One week of oral Camostat vs placebo in non-hospitalized adults with COVID-19
• Assessment of the available therapeutic approaches for severe COVID-19 (Nature)
• Optimal duration of systemic Corticosteroids in COVID-19 treatment (OFID)
• Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and in patients with long-COVID syndrome (Nature)
• Local budesonide therapy in the management of persistent hyposmia in suspected COVID-19 patients (JID)
• Safety profile and clinical and virological outcomes of Nirmatrelvir-Ritonavir treatment in patients with Kidney disease and COVID-19
• Contribute to our Floating Doctors fundraiser at PWB
• Letters read on TWiV 1052
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]